You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 25, 2024

bydureon Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Bydureon, and when can generic versions of Bydureon launch?

Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. There are twenty-one patents protecting this drug.

This drug has three hundred and seventy-seven patent family members in forty-eight countries.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the exenatide synthetic profile page.

DrugPatentWatch® Generic Entry Outlook for Bydureon

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 20, 2027. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Ask!
Questions you can ask:
  • What is the 5 year forecast for bydureon?
  • What are the global sales for bydureon?
  • What is Average Wholesale Price for bydureon?
Summary for bydureon
International Patents:377
US Patents:12
Applicants:1
NDAs:2
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 39
Drug Prices: Drug price information for bydureon
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for bydureon
What excipients (inactive ingredients) are in bydureon?bydureon excipients list
DailyMed Link:bydureon at DailyMed
Drug patent expirations by year for bydureon
Drug Prices for bydureon

See drug prices for bydureon

Drug Sales Revenue Trends for bydureon

See drug sales revenues for bydureon

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for bydureon
Generic Entry Date for bydureon*:
⤷  Subscribe
Constraining patent/regulatory exclusivity:
8,501,698*PED
NDA:
022200
Dosage:
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for bydureon

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The University of Texas Health Science Center, HoustonPhase 2
University of WashingtonPhase 3
Dasman Diabetes InstitutePhase 4

See all bydureon clinical trials

US Patents and Regulatory Information for bydureon

bydureon is protected by twelve US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of bydureon is ⤷  Subscribe.

This potential generic entry date is based on patent 8,501,698.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No 8,216,180*PED ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No 8,361,972*PED ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No 8,431,685*PED ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No 7,612,176*PED ⤷  Subscribe Y ⤷  Subscribe
Astrazeneca Ab BYDUREON PEN exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-002 Feb 28, 2014 DISCN Yes No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Astrazeneca Ab BYDUREON BCISE exenatide synthetic SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 209210-001 Oct 20, 2017 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Subscribe

Expired US Patents for bydureon

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 6,872,700 ⤷  Subscribe
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 5,424,286 ⤷  Subscribe
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 9,198,925 ⤷  Subscribe
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 7,741,269 ⤷  Subscribe
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 6,858,576 ⤷  Subscribe
Astrazeneca Ab BYDUREON exenatide synthetic FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS 022200-001 Jan 27, 2012 6,936,590 ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or Subscribe

International Patents for bydureon

When does loss-of-exclusivity occur for bydureon?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 1730
Patent: ESTRUCTURAS DE CRISTAL DE INHIBIDORES SGLT2 Y PROCESOS PARA PREPARAR LOS MISMOS
Estimated Expiration: ⤷  Subscribe

Australia

Patent: 07265246
Patent: Crystalline solvates and complexes of (IS) -1, 5-anhydro-L-C- (3- ( (phenyl) methyl) phenyl) -D-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes
Estimated Expiration: ⤷  Subscribe

Brazil

Patent: 0713544
Patent: solvatos cristalinos complexos de derivados de (1s)-1,5-anidro-1-c-(3-((fenil) metil)fenil)-d-glucitol com aminoÁcidos como inibidores de sglt2 para o tratamento de diabetes
Estimated Expiration: ⤷  Subscribe

Patent: 2017015106
Patent: estrutura de cristal de formula 1b e composição farmacêutica
Estimated Expiration: ⤷  Subscribe

Patent: 2017021516
Patent: processo de preparação de uma estrutura de cristal de solvato de (s)-propileno glicol de fórmula ia
Estimated Expiration: ⤷  Subscribe

Canada

Patent: 53344
Patent: SOLVATES CRISTALLINS ET COMPLEXES DE DERIVES DE (IS)-1,5-ANHYDRO-L-C-{3-[(PHENYL)METHYL]PHENYL}-D-GLUCITOL AVEC DES ACIDES AMINES EN TANT QU'INHIBITEURS DE SGLT2 POUR LE TRAITEMENT DU DIABETE (CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS ASSGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 24318
Patent: SOLVATES CRISTALLINS ET COMPLEXES DE DERIVES DE (IS)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL-D-GLUCITOL AVEC DES ACIDES AMINES EN TANT QU'INH IBITEURS DE SGLT2 POUR LE TRAITEMENT DU DIABETE (CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 85797
Patent: SOLVATES CRISTALLINS ET COMPLEXES DE DERIVES DE (IS)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL-D-GLUCITOL AVEC DES ACIDES AMINES EN TANT QU'INH IBITEURS DE SGLT2 POUR LE TRAITEMENT DU DIABETE (CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Chile

Patent: 07001915
Patent: Compuesto cristalino de 6-[4-cloro-3-(4-etoxibencil)fenil]tetrahidropiran-2,3,4,5,-tetraol; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y su uso para preparar un medicamento para tratar diabetes, dislipidemia, obesidad, entre otras.
Estimated Expiration: ⤷  Subscribe

China

Patent: 1479287
Patent: Crystalline solvates and complexes of (is) -1, 5-anhydro-l-c- (3- ( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
Estimated Expiration: ⤷  Subscribe

Patent: 3145773
Patent: Crystalline solvates and complexes of (IS) -1, 5-anhydro-L-C- (3- ( (phenyl) methyl) phenyl) -D-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes
Estimated Expiration: ⤷  Subscribe

Colombia

Patent: 60299
Patent: SOLVATOS CRISTALINOS Y COMPLEJOS DE DERIVADOS DE (1S)-1,5-ANHIDRO-1-C-(3-((FENIL)METIL)FENIL)-D-GLUCITOL CON AMINOÁCIDOS COMO INHIBIDORES SGLT2 PARA EL TRATAMIENTO DE DIABETES.
Estimated Expiration: ⤷  Subscribe

Croatia

Patent: 0141007
Estimated Expiration: ⤷  Subscribe

Cyprus

Patent: 15738
Estimated Expiration: ⤷  Subscribe

Denmark

Patent: 69374
Estimated Expiration: ⤷  Subscribe

Eurasian Patent Organization

Patent: 8229
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-C-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА (CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 0428
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-С-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА (CRYSTALLINE SOLVATES OF (IS)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 8259
Patent: КРИСТАЛЛИЧЕСКИЙ СОЛЬВАТ ПРОИЗВОДНОГО (1S)-1,5-АНГИДРО-1-C-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТОЙ И СПОСОБ ЕГО ПОЛУЧЕНИЯ (CRYSTALLINE SOLVATE OF (1S)-1,5-ANHYDRO-L-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVE WITH AMINO ACID AND PROCESS FOR PREPARING THE SAME)
Estimated Expiration: ⤷  Subscribe

Patent: 5999
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-C-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА (CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 0900066
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-C-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ) -D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА
Estimated Expiration: ⤷  Subscribe

Patent: 1171333
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-С-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА
Estimated Expiration: ⤷  Subscribe

Patent: 1490902
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-C-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА
Estimated Expiration: ⤷  Subscribe

Patent: 1791254
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-C-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА
Estimated Expiration: ⤷  Subscribe

Patent: 2091391
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (1S)-1,5-АНГИДРО-1-C-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ В КАЧЕСТВЕ ИНГИБИТОРОВ SGLT2 ДЛЯ ЛЕЧЕНИЯ ДИАБЕТА
Estimated Expiration: ⤷  Subscribe

European Patent Office

Patent: 69374
Patent: SOLVATES CRISTALLINS DE DÉRIVÉS DE (1S)-1,5-ANHYDRO-1-C-(3-((PHÉNYL)MÉTHYL)PHÉNYL)-D-GLUCITOL AVEC DES ALCOHOLS EN TANT QU'INHIBITEURS DE SGLT2 POUR LE TRAITEMENT DU DIABÈTE (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 57918
Patent: Solvates cristallins et complexes de dérivés de (1S)-1,5-anhydro-1-C-((phényl)méthyl) phényl)-d-glucitol avec acides aminés en tant qu'inhibiteurs SGLT2 pour le traitement des diabètes (Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl) methyl) phenyl)-d-glucitol derivatives with amino acids as SGLT2 inhibitors for the treatment of diabetes)
Estimated Expiration: ⤷  Subscribe

Patent: 45466
Patent: SOLVATE DE PROPYLENE GLYCOLE DE (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ÉTHOXY-BENZYL)-PHÉNYL]-6-HYDROXYMÉTHYL-2-MÉTHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL EN TANT QU'INHIBITEURS DU SGLT2 POUR LE TRAITEMENT DU DIABÈTE ((2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL PROPYLENE GLYCOL SOLVATE AS SGT2 INHIBITOR FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 63807
Patent: COMPOSITION PHARMACEUTIQUE COMPRENANT SOLVATE DE (S)-PROPYLENE GLYCOL DE (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ÉTHOXY-BENZYL)-PHÉNYL]-6-HYDROXYMÉTHYL-2-MÉTHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL CRISTALLINE (PHARMACEUTICAL COMPOSITION COMPRISING CRYSTALLINE (2S,3R,4S,5S,6R)-2-[4-CHLORO-3-(4-ETHOXY-BENZYL)-PHENYL]-6-HYDROXYMETHYL-2-METHOXY-TETRAHYDRO-PYRAN-3,4,5-TRIOL (S)-PROPYLENE GLYCOL SOLVATE)
Estimated Expiration: ⤷  Subscribe

Hong Kong

Patent: 27359
Patent: 用於治療糖尿病的 抑製劑的 -脫水- 苯基 甲基 苯基 -葡萄糖醇衍生物與醇的結晶溶劑合物 (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)- D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES SGLT2 (1S)-15--1-C-(3 -(()))-D-)
Estimated Expiration: ⤷  Subscribe

Israel

Patent: 5882
Patent: צורות גבישיות של נגזרות של (1 s)-1, 5-אנהידרו-1- c -(3-((פניל)מתיל)פניל)-d-גלוציטול עם חומצות אמיניות ושימוש בהן לטיפול בסכרת (Crystalline forms of (1s)-1,5-anhydro-1-c-(3-(phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids and use thereof for the treatment of diabetes)
Estimated Expiration: ⤷  Subscribe

Patent: 4180
Patent: סולבטים גבישיים וקומפלקסים של נגזרות של (s1) -1, 5 אנהידרו- 1 - c - ( 3- ((פניל(מתיל(פניל)-d- גלוציטול עם חומצות אמינו המשמשים כמעכבי sglt2 עבור הטיפול בסוכרת (Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes)
Estimated Expiration: ⤷  Subscribe

Patent: 4181
Patent: סולבטים גבישיים וקומפלקסים של נגזרות -1,51)(s-אנהידרו(3--1-c-((פניל)מתיל)פניל)-d-גלוציטול עם חומצות אמינו המשמשים כמעכבי 2sglt עבור הטיפול בסוכרת (Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes)
Estimated Expiration: ⤷  Subscribe

Patent: 4182
Patent: סולבטים גבישיים וקומפלקסים של נגזרות 1s))-5,1-אנהידרו-1-c-(3-((פניל)מתיל)פניל)-d-גלוציטול עם חומצות אמינו המשמשים כמעכבי 2sglt עבור הטיפול בסוכרת (Crystalline solvates and complexes of (1s)-1,5-anhydro-1-c-(3-((phenyl)methyl)phenyl)-d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes)
Estimated Expiration: ⤷  Subscribe

Japan

Patent: 13889
Estimated Expiration: ⤷  Subscribe

Patent: 66651
Estimated Expiration: ⤷  Subscribe

Patent: 37187
Estimated Expiration: ⤷  Subscribe

Patent: 09545525
Estimated Expiration: ⤷  Subscribe

Patent: 13209394
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Patent: 15071636
Patent: 糖尿病の治療用ＳＧＬＴ２阻害剤としてのアミノ酸を有する（１Ｓ）−１，５−アンヒドロ−１−Ｃ−（３−（（フェニル）メチル）フェニル）−Ｄ−グルシトール誘導体の結晶性溶媒和物および複合体 (CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 16172758
Patent: 糖尿病の治療用ＳＧＬＴ２阻害剤としてのアミノ酸を有する（１Ｓ）−１，５−アンヒドロ−１−Ｃ−（３−（（フェニル）メチル）フェニル）−Ｄ−グルシトール誘導体の結晶性溶媒和物および複合体 (CRYSTALLINE SOLVATES AND COMPLEXES OF (IS)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 17222681
Patent: 糖尿病の治療用ＳＧＬＴ２阻害剤としてのアミノ酸を有する（１Ｓ）−１，５−アンヒドロ−１−Ｃ−（３−（（フェニル）メチル）フェニル）−Ｄ−グルシトール誘導体の結晶性溶媒和物および複合体 (CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Patent: 19059779
Patent: 糖尿病の治療用ＳＧＬＴ２阻害剤としてのアミノ酸を有する（１Ｓ）−１，５−アンヒドロ−１−Ｃ−（３−（（フェニル）メチル）フェニル）−Ｄ−グルシトール誘導体の結晶性溶媒和物および複合体 (CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES HAVING AMINO ACIDS AS SGLT2 INHIBITORS FOR TREATING DIABETES)
Estimated Expiration: ⤷  Subscribe

Malaysia

Patent: 8566
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5- ANHYDRO-1 -C-(3-( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Patent: 3930
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (IS)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Mexico

Patent: 9143
Patent: SOLVATOS Y COMPLEJOS CRISTALINOS DE LOS DERIVADOS DE (1S)-1,5-ANHIDRO-1-C-(3-((FENIL)METIL)FENIL)-D-GLUCITOL CON AMINOACIDOS COMO INHIBIDORES DE SGLT2 PARA EL TRATAMIENTO DE LA DIABETES. (CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES.)
Estimated Expiration: ⤷  Subscribe

Patent: 7155
Patent: SOLVATOS Y COMPLEJOS CRISTALINOS DE LOS DERIVADOS DE (1S)-1, 5-ANHIDRO-1-C- (3-((FENIL) METIL) FENIL) -D-GLUCITOL CON AMINOÁCIDOS COMO INHIBIDORES DE SGLT2 PARA EL TRATAMIENTO DE LA DIABETES. (CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES.)
Estimated Expiration: ⤷  Subscribe

Patent: 08015377
Patent: SOLVATOS Y COMPLEJOS CRISTALINOS DE LOS DERIVADOS DE (1S) - 1,5-ANHIDRO-1-C-(3-((FENIL)METIL)FENIL)-D-GLUCITOL CON AMINOACIDOS COMO INHIBIDORES DE SGLT2 PARA EL TRATAMIENTO DE LA DIABETES. (CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES.)
Estimated Expiration: ⤷  Subscribe

New Zealand

Patent: 4346
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Patent: 9190
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Patent: 9195
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Patent: 9202
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Norway

Patent: 6828
Estimated Expiration: ⤷  Subscribe

Patent: 7770
Estimated Expiration: ⤷  Subscribe

Patent: 085169
Estimated Expiration: ⤷  Subscribe

Patent: 221233
Patent: Krystallinske solvater og komplekser av (1S)-1,5-anhydro-1-C-(3-((fenyl)metyl)fenyl)-D-glucitol-derivater med aminosyrer som SGLT2-inhibitorer for behandling av diabetes
Estimated Expiration: ⤷  Subscribe

Peru

Patent: 080349
Patent: ESTRUCTURAS DE CRISTAL DE INHIBIDORES SGLT2 Y PROCESOS PARA PREPARAR LOS MISMOS
Estimated Expiration: ⤷  Subscribe

Patent: 120776
Patent: ESTRUCTURAS CRISTALINAS DE DAPAGLIFLOZIN Y SUS PROCESOS DE PREPARACION
Estimated Expiration: ⤷  Subscribe

Philippines

Patent: 012500168
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (IS)-1,5-ANHYDRO-L-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Poland

Patent: 69374
Estimated Expiration: ⤷  Subscribe

Portugal

Patent: 69374
Estimated Expiration: ⤷  Subscribe

Serbia

Patent: 638
Patent: KRISTALNI SOLVATI DERIVATA (1S)-1,5-ANHIDRO-1-C-(3-((FENIL) METIL) FENIL)-D-GLUCITOLA SA ALKOHOLIMA KAO INHIBITORI SGLT2 ZA TRETMAN DIJABETESA (CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Singapore

Patent: 2741
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Patent: 201402181S
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Slovenia

Patent: 69374
Estimated Expiration: ⤷  Subscribe

South Africa

Patent: 0810475
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (IS)-1,5-ANHYDRO-L-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

South Korea

Patent: 1493102
Estimated Expiration: ⤷  Subscribe

Patent: 090023643
Patent: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL)METHYL)PHENYL)-D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES
Estimated Expiration: ⤷  Subscribe

Spain

Patent: 21665
Estimated Expiration: ⤷  Subscribe

Patent: 59862
Estimated Expiration: ⤷  Subscribe

Patent: 69130
Estimated Expiration: ⤷  Subscribe

Taiwan

Patent: 21245
Estimated Expiration: ⤷  Subscribe

Patent: 66876
Estimated Expiration: ⤷  Subscribe

Patent: 19528
Estimated Expiration: ⤷  Subscribe

Patent: 0811127
Patent: Crystal structures of SGLT2 inhibitors and processes for preparing same
Estimated Expiration: ⤷  Subscribe

Patent: 1406743
Patent: Crystal structures of SGLT2 inhibitors and processes for preparing same
Estimated Expiration: ⤷  Subscribe

Patent: 1509927
Patent: Crystal structures of SGLT2 inhibitors and processes for preparing same
Estimated Expiration: ⤷  Subscribe

Patent: 1546054
Patent: Crystal structures of SGLT2 inhibitors and processes for preparing same
Estimated Expiration: ⤷  Subscribe

Ukraine

Patent: 765
Patent: КРИСТАЛЛИЧЕСКИЕ СОЛЬВАТЫ И КОМПЛЕКСЫ ПРОИЗВОДНЫХ (IS)-1,5-АНГИДРО-L-C-(3-((ФЕНИЛ)МЕТИЛ)ФЕНИЛ)-D-ГЛЮЦИТОЛА С АМИНОКИСЛОТАМИ КАК ИНГИБИТОРЫ БЕЛКА SGLT2, ПРИГОДНЫЕ В ЛЕЧЕНИИ ДИАБЕТА;КРИСТАЛІЧНІ СОЛЬВАТИ І КОМПЛЕКСИ ПОХІДНИХ (IS)-1,5-АНГІДРО-L-C-(3-((ФЕНІЛ)МЕТИЛ)ФЕНІЛ)-D-ГЛЮЦИТОЛУ З АМІНОКИСЛОТАМИ ЯК ІНГІБІТОРИ БІЛКА SGLT2, ПРИДАТНІ У ЛІКУВАННІ ДІАБЕТУ (CRYSTALLINE SOLVATES AND COMPLEXES OF (IS) -1, 5-ANHYDRO-L-C- (3- ((PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES)
Estimated Expiration: ⤷  Subscribe

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering bydureon around the world.

Country Patent Number Title Estimated Expiration
Lithuania 3524261 ⤷  Subscribe
Germany 69739172 ⤷  Subscribe
Austria 417622 ⤷  Subscribe
New Zealand 536605 C-aryl glucoside inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2) ⤷  Subscribe
Taiwan 200948408 Ampoule comprising an ampoule holder ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2008122132 ⤷  Subscribe
>Country >Patent Number >Title >Estimated Expiration

Subscribe to access the full database, or Subscribe

Supplementary Protection Certificates for bydureon

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1734971 91989 Luxembourg ⤷  Subscribe 91989, EXPIRES: 20260617
1734971 248 5006-2012 Slovakia ⤷  Subscribe PRODUCT NAME: EXENATID; REGISTRATION NO/DATE: EU/1/11/696/001 - EU/1/11/696/002 20110623
1506211 18/2013 Austria ⤷  Subscribe PRODUCT NAME: DAPAGLIFLOZIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
1506211 C01506211/01 Switzerland ⤷  Subscribe PRODUCT NAME: DAPAGLIFLOZIN; REGISTRATION NO/DATE: SWISSMEDIC 65176 19.08.2014
1734971 C300526 Netherlands ⤷  Subscribe PRODUCT NAME: EXENATIDE; REGISTRATION NO/DATE: EU/1/11/696/001-002 20110617
1734971 16/2012 Austria ⤷  Subscribe PRODUCT NAME: EXENATID; REGISTRATION NO/DATE: EU/1/11/696/001-002 (MITTEILUNG) 20110623
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Subscribe to access the full database, or Subscribe

Bydureon Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Bydureon

Introduction

Bydureon, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been a significant player in the treatment of type 2 diabetes since its introduction by AstraZeneca. Here, we delve into the market dynamics and financial trajectory of Bydureon, highlighting its evolution, challenges, and future prospects.

Historical Context and Evolution

Bydureon was first introduced in 2012 as a once-weekly therapy, building on the success of its predecessor, Byetta, which was the first GLP-1 receptor agonist to hit the market in 2005. Initially, Bydureon required users to mix ingredients and assemble the syringe, a process that was not user-friendly. However, AstraZeneca later improved the formulation by introducing a more convenient auto-injector device[4].

Market Performance and Sales

Bydureon's sales have faced significant challenges in recent years. Despite being a pioneer in the GLP-1 market, Bydureon has been squeezed by competitors such as Eli Lilly's Trulicity, Merck’s Januvia, and Novo Nordisk’s Victoza and Ozempic. This competition has led to a decline in sales for Bydureon and its predecessor, Byetta[4].

Clinical Trials and Regulatory Approvals

A recent significant development for Bydureon is its completion of a phase 3 trial in children and adolescents with type 2 diabetes. This trial, presented at the American Diabetes Association’s 81st Scientific Sessions, showed promising results, reducing A1C levels over 24 weeks. This could pave the way for FDA approval and provide a much-needed treatment option for an underserved patient population[4].

Market Dynamics

Competitive Landscape

The GLP-1 receptor agonist market is highly competitive, with several strong players. Bydureon faces intense competition from newer and more potent GLP-1 agonists. For instance, Novo Nordisk’s oral semaglutide is gaining traction, which could further challenge Bydureon’s market share[4].

Patient Population and Demand

There is an expanding younger patient population with type 2 diabetes, which presents an opportunity for Bydureon. The trial results in children and adolescents indicate that Bydureon can make a significant difference in this demographic, potentially increasing its market demand[4].

Geographical Expansion

While Bydureon has a global presence, its sales are impacted by regional market dynamics. For example, the implementation of the Value-Based Purchasing (VBP) program in China has affected the sales of various diabetes medications, including those from AstraZeneca[2].

Financial Trajectory

Revenue Trends

Bydureon's revenue has been declining due to the intense competition in the GLP-1 market. AstraZeneca's overall diabetes franchise, which includes Bydureon and Byetta, has seen sales drop as newer medications gain market share[4].

Cost and Pricing

The financial performance of Bydureon is also influenced by its pricing strategy. With generic competitors and newer, more effective medications entering the market, AstraZeneca may need to adjust pricing to remain competitive. However, this could impact the profitability of the drug[4].

Research and Development Investments

AstraZeneca continues to invest in research and development, including new formulations and indications for Bydureon. These investments are crucial for maintaining market relevance and potentially expanding the drug's use into new patient populations[2].

Future Prospects

Regulatory Approvals and New Indications

The potential FDA approval for Bydureon in children and adolescents with type 2 diabetes could revitalize the drug's market presence. New indications and approvals can help Bydureon regain some of its lost market share[4].

Product Innovations

Improvements in the delivery mechanism, such as the auto-injector device, have made Bydureon more user-friendly. Continued innovation in product formulation and delivery could enhance patient compliance and satisfaction, potentially boosting sales[4].

Strategic Partnerships

Collaborations with healthcare providers, research institutions, and other industry players can help AstraZeneca access new markets and patient populations. Strategic partnerships can also facilitate joint research efforts and knowledge exchange, which could lead to new opportunities for Bydureon[3].

Key Takeaways

  • Competitive Landscape: Bydureon faces significant competition from newer GLP-1 agonists.
  • Clinical Trials: Recent trials in children and adolescents with type 2 diabetes show promising results.
  • Market Dynamics: Expanding younger patient population and geographical expansion present opportunities.
  • Financial Trajectory: Revenue decline due to competition, with potential for revival through new approvals and innovations.
  • Future Prospects: Regulatory approvals, product innovations, and strategic partnerships are crucial for Bydureon’s future.

FAQs

  1. What is Bydureon, and how does it differ from other GLP-1 agonists? Bydureon is a once-weekly GLP-1 receptor agonist used to treat type 2 diabetes. It differs from other GLP-1 agonists in its delivery mechanism, having evolved from a twice-daily to a once-weekly auto-injector form.

  2. Why has Bydureon's sales been declining? Bydureon's sales have declined due to intense competition from newer and more potent GLP-1 agonists like Trulicity, Januvia, Victoza, and Ozempic.

  3. What are the recent clinical trial results for Bydureon? Recent phase 3 trials have shown that Bydureon can effectively reduce A1C levels in children and adolescents with type 2 diabetes, potentially paving the way for FDA approval.

  4. How does Bydureon's market performance compare globally? Bydureon's market performance varies globally, with regional factors such as the VBP program in China impacting sales. However, it maintains a global presence and is seeking to expand into new patient populations.

  5. What are the future prospects for Bydureon? Future prospects include potential FDA approval for new indications, continued product innovations, and strategic partnerships to access new markets and patient populations.

Sources

  1. AstraZeneca Full-year and Q4 2023 results announcement[1]
  2. AstraZeneca Full year and Q4 2022 results[2]
  3. Global Exenatide market 2024-2032[3]
  4. ADA 2021: AstraZeneca touts Bydureon trial win in children and adolescents with type 2 diabetes[4]

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
 NCE-1 Patent Challenge Dates 2024 - 2025
 Trigger-based marketing for the life sciences
 Get DrugPatentWatch Business Intelligence Reports at Amazon.com
 DrugChatter - AI-based answers to questions about drugs
 RxJam - Digital Marketing for Life Sciences
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links

Follow DrugPatentWatch:

  DrugPatentWatch Linkedin Group